STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Laurence Lytton Discloses 1.0% Stake in Exagen (XGN) via Schedule 13G/A

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Exagen Inc. reporting person Laurence W. Lytton discloses beneficial ownership of 216,840 shares of common stock, representing 1.0% of the outstanding class. The filing states Mr. Lytton has sole voting and sole dispositive power over these shares, with no shared authority reported.

The statement affirms the shares are not held to influence control of the issuer and the reporting person certifies the accuracy of the disclosure. The filing indicates the position is not part of any group and no other parties are identified as holding power over the securities.

Positive

  • None.

Negative

  • None.

Insights

TL;DR Small, disclosed stake: 216,840 shares (1.0%) held with sole voting and dispositive power; limited market impact.

The disclosure shows a non-controlling position by an individual holder with direct control of the shares. At 1.0% of the class, this holding does not meet common materiality thresholds for activism or control attempts. The clear statement of sole voting and dispositive power is procedurally important for transparency but does not signal a strategic change in governance or capital structure based on the information provided.

TL;DR Ownership is transparent and certified; no indication of group action or intent to influence issuer control.

The filing identifies the reporting person and documents sole authority over 216,840 shares while explicitly stating the position was not acquired to influence control. For governance monitoring, this is routine disclosure complying with beneficial ownership rules. There is no evidence in the filing of coordinated activity, reliance on derivatives, or other arrangements that would raise governance or control concerns.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: Percentage calculated based on 22,003,641 shares of Common Stock outstanding as of July 24, 2025, as reported in the Form 10-Q filed by the issuer on July 29, 2025.


SCHEDULE 13G



LYTTON LAURENCE W
Signature:/s/ Laurence W. Lytton
Name/Title:Reporting person
Date:08/13/2025

FAQ

What stake does Laurence W. Lytton report in Exagen (XGN)?

The filing reports 216,840 shares, representing 1.0% of Exagen's common stock.

Does Laurence W. Lytton have voting control over the shares reported for XGN?

Yes. The filing shows sole voting power and sole dispositive power for the 216,840 shares.

Is the reported position part of a group or held on behalf of another person?

No. The filing states the position is not part of a group and is not held on behalf of another person.

Was the stake acquired to influence control of Exagen (XGN)?

No. The reporting person certifies the securities were not acquired to change or influence control of the issuer.

Who signed the Schedule 13G/A filing for this disclosure?

The filing is signed by the reporting person, identified as Laurence W. Lytton.
Exagen Inc.

NASDAQ:XGN

XGN Rankings

XGN Latest News

XGN Latest SEC Filings

XGN Stock Data

169.75M
15.85M
15.29%
57.82%
2.99%
Diagnostics & Research
Services-medical Laboratories
Link
United States
VISTA